Clinical significance and predictive value of prostaglandin E2 receptors (EPR) 1 - 4 in patients with renal cell carcinoma

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 597-605

  Ohba, Kojiro ^a   Miyata, Yasuyoshi ^a   Watanabe, Shin Ichi ^a   Hayashi, Tomayoshi ^b   Kanetake, Hiroshi ^a   Kanda, Shigeru ^c   Sakai, Hideki ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Immunohistochemistry; Pathological features; Prostaglandin E2 receptor; Renal cell carcinoma; Survival

Indexed keywords

PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1 RECEPTOR; PROSTAGLANDIN E3 RECEPTOR; PROSTAGLANDIN E4 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUBULE CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; WESTERN BLOTTING;

CARCINOMA, RENAL CELL; CELL MEMBRANE; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTORS, PROSTAGLANDIN E; SURVIVAL RATE;

EID: 79953247727     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB and Dannenberg AJ: Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 56: 4424-4429, 1996. (Pubitemid 26330450)
2. Li G, Yang T and Yan J: Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun 299: 886-890, 2002. (Pubitemid 36034569)
3. Kase S, Osaki M, Honjo S, Adachi H, Tsujitani S, Kaibara N and Ito H: Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch 442: 129-135, 2003. (Pubitemid 36337660)
4. Chen Q, Shinohara N, Abe T, Harabayashi T and Nonomura K: Impact of cyclooxygenase-2 gene expression on tumor invasiveness in human renal carcinoma cell line. J Urol 172: 2153-2157, 2004. (Pubitemid 39507481)
5. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J and Koki AT: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637-2645, 2000.
6. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P and Härkönen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57: 1276-1280, 1997.
7. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H and Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001, 1998. (Pubitemid 28521147)
8. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT and Fahey TJ 3rd: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59: 987-990, 1999. (Pubitemid 29135954)
9. Reddy BS, Rao CV and Seibert K: Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56: 4566-4569, 1996. (Pubitemid 26338047)
10. Brown JR and BuBois RN: Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10: 4266s-4269s, 2004.
11. Lieberman R: Chemoprevention of prostate cancer: current status and feature directions. Cancer Metastasis Rev 21: 297-309, 2001.
12. Roumie CL, Choma NN, Kaltenbach L, Mitchel EF Jr., Arbogast PG and Griffin MR: Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiology Drug Saf 18: 1053-1056, 2009.
13. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER and Demets DL: Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372: 1756-1764, 2008.
14. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M and Dubinett SM: Prostaglandin E 2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65: 6275-6281, 2005. (Pubitemid 40994413)
15. Rigas B, Goldman IS and Levine L: Altered eicosanoid levels in human colon cancer: J Lab Clin Med 122: 518-523, 1993 (Pubitemid 23352474)
16. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, Subbaramaiah K and Dannenberg AJ: Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 7: 3971-3976, 2001. (Pubitemid 34044615)
17. min/+ mice. Cancer Res 62: 403-408, 2002. (Pubitemid 34106412)
18. Zweifel BS, Davis TW, Ornberg RL and Masferrer JL: Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E 2 in human head and neck xenograft tumors. Cancer Res 62: 6706-6711, 2002. (Pubitemid 35364141)
19. Negishi M, Sugimoto Y and Ichikawa A: Molecular mechanisms of diverse action of prostanoid receptors. Biochim Biophys Acta 1259: 109-119, 1995.
20. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T and Wakabayashi K: Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59: 5093-5096, 1999. (Pubitemid 29503965)
21. Yano T, Zissel G, Muller-Qernheim J, Jae Sin S, Satoh H and Ichikawa T: Prostaglandin E 2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett 518: 154-158, 2002. (Pubitemid 34454983)
22. Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, Shimonishi M, Tanabe T, Sugimoto Y, Ichikawa A, Mutoh M, Tanaka N and Miwa M: Expression of cyclooxygenase-2 and prostaglandin E- receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res 8: 1157-1167, 2002. (Pubitemid 35177370)
23. Jabbour HN, Milne SA, Williams AR, Anderson RA and Boddy SC: Expression of COX-2 and PGE synthase and synthesis of PGE(2) in endometrial adenocarcinoma: a possible autocrine/ paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J cancer 85: 1023-1031, 2001. (Pubitemid 33016005)
24. Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP and Jabbour HN: Cyclooxygenase-2 expression and prostaglandin E 2 synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 86: 2243-2249, 2001. (Pubitemid 32472947)
25. Kawamori T, Uchiya N, Nakatsugi S, Watanabe K, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Sugimura T and Wakabayashi K: Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP1 antagonists, on breast cancer development. Carcinogenesis 22: 2001-2004, 2001.
26. Miyata Y, Kanda S, Maruta S, Matsuo T, Sakai H, Hayashi T and Kanetake H: Relationship between prostaglandin E 2 receptors and clinicopathologic features in human prostate cancer tissue. Urology 68: 1360-1365, 2006. (Pubitemid 44880382)
27. Sheng H, Shao J, Washington MK and DuBois RN: Prostaglandin E 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075-18081, 2001.
28. Miyata Y, Ohba K, Kanda S, Nomata K, Eguchi J, Hayashi T and Kanetake H: Pathological function of prostaglandin E 2 receptors in transitional cell carcinoma of the upper urinary tract. Virchows Arch 448: 822-829, 2006. (Pubitemid 43824440)
29. Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebeis M, Karl A and Stief CG: Sorafenib after combination therapy with gemcitabin and doxorubicine in patients with sarcomatoid renal cell carcinoma: A prospective evaluation. Eur J Med Res 26: 287-291, 2010.
30. Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB and Mier JW: Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 9: 2793-2802, 2010.
31. Fuhrman SA, Lasky LC and Limas CL: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982. (Pubitemid 13234762)
32. Golijanin D, Tan JY, Kazior A, Cohen EG, Russo P, Dalbagni G, Auborn KJ, Subbaramaiah K and Dannenberg AJ: Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin Cancer Res 10: 1024-1031, 2004. (Pubitemid 38198904)
33. Herman MB, Rajkhowa T, Cutuli F, Springate JE and Taub ML: Regulation of renal proximal tubule Na-K-ATPase by prostaglandins. Am J Physiol Renal Physiol 298: F1222-F1234, 2010.
34. Timoshenko AV, Xu G, Chakarabarti S, Lala PK and Chakraborty C: Role of prostaglandin E 2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 289: 265-274, 2003.
35. Yang L, Huang Y, Porta R, Yanagisawa K, Gonzalez A, Segi E, Johnson DH, Narumiya S and Carbone DP: Host and Direct antitumoral effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 66: 9665-9672, 2006.
36. Sharma SD, Meeran SM and Katiyar SK: Proanthyanidins inhibit in vitro and in vivo growth of human non-small cell lung cancer cells by inhibiting the prostaglandin E 2 and prostaglandin E 2 receptors. Mol Cancer Ther 9: 569-580, 2010.
37. Spinella F, Rosanò L, Di Castro V, Natali PG and Bagnato A: Endothelin-1-induced prostaglandin E 2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 279: 46700-46705, 2004.
38. Pan MR, Hou MF, Chang HC and Hung WC: Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem 283: 11155-11163, 2008.
39. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S and Dubinett SM: Autocrine/paracrine prostaglandin E 2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 277: 50828-50833, 2002. (Pubitemid 36042248)
40. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T and Kanetake H: Expression of cycrooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9: 1741-1749, 2003. (Pubitemid 36554599)
41. Yu L, Wu WK, Li ZJ, Li HT, Wu YC and Cho CH: Prostaglandin E(2) promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway-dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells. Int J Cancer 125: 2540-2546, 2009.
42. Ansari KM, Sung YM, He G and Fisher SM: Prostaglandin receptor EP2 is responsible for cyclooxygenase-2 induction by prostaglandin E 2 in mouse skin. Carcinogenesis 28: 2063-2068, 2007.
43. Sinha P, Clements VK, Fulton AM and Ostrand-Rosenberg S: Prostaglandin E 2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67: 4507-4513, 2007. (Pubitemid 46815102)
44. Alaa M, Suzuki M, Yoshino M, Tian L, Suzuki H, Nagato K, Fujiwara T, Wada H, Moriya Y, Hoshino H, Motohashi S, Yoshida S, Shibuya K, Hiroshima K, Nakatani Y, Abdrabou A, Elkholy M, Mahfouz T and Yoshino I: Prostaglandin E 2 receptor 2 overexpression in squamous cell carcinoma of the lung correlated with p16 INK4A methylation and an unfavorable prognosis. Int J Oncol 34: 805-812, 2009.
45. Kuo K-T, Wang H-W, Chou T-Y, Hsu WH, Lin CH and Wang LS: Prognostic role of PGE 2 receptor EP2 in esophageal squamous cell carcinoma. Ann Surg Oncol 16: 352-360, 2009.
46. Han C, Michalopoulos GK and Wu T: Prostaglandin E 2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J cell Physiol 207: 261-270, 2006.
47. Hull MA, Ko SC and Hawcroft G: Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 3: 1031-1039, 2004.
48. Fulton AM, Ma X and Kundu N: Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 66: 9794-9797, 2006. (Pubitemid 44672027)